Clinical implementation of intensity-modulated arc therapy (IMAT) for rectal cancer by DUTHOY, WIM et al.
CT
a
l
a
B
w
t
g
V
1
Int. J. Radiation Oncology Biol. Phys., Vol. 60, No. 3, pp. 794–806, 2004
Copyright © 2004 Elsevier Inc.
Printed in the USA. All rights reserved
0360-3016/04/$–see front matterdoi:10.1016/j.ijrobp.2004.04.016
LINICAL INVESTIGATION Rectum
CLINICAL IMPLEMENTATION OF INTENSITY-MODULATED ARC THERAPY
(IMAT) FOR RECTAL CANCER
WIM DUTHOY, M.D.,* WERNER DE GERSEM, IR.,* KOEN VERGOTE, M.SC.,*
TOM BOTERBERG, M.D., PH.D.,* CRISTINA DERIE, G.N.,* PETER SMEETS, M.D.,†
CARLOS DE WAGTER, IR., PH.D.,* AND WILFRIED DE NEVE, M.D., PH.D.*
Departments of *Radiotherapy and †Radiology, Ghent University Hospital, Ghent, Belgium
Purpose: In rectal cancer, combined radiotherapy and chemotherapy, either pre- or postoperatively, is an
accepted treatment. Late small bowel (SB) toxicity is a feared side effect and limits radiation-dose escalation in
a volume-dependent way. A planning strategy for intensity- modulated arc therapy (IMAT) was developed, and
IMAT was clinically implemented with the aim to reduce the volume of SB irradiated at high doses and thus
reduce SB toxicity. We report on the treatment plans of the first 7 patients, on the comparison of IMAT with
conventional 3D planning (3D), and on the feasibility of IMAT delivery.
Methods and Materials: Seven patients, who were referred to our department for preoperative (n  4) or
postoperative (n  3) radiotherapy for rectal cancer, gave written consent for IMAT treatment. All patients
had a planning CT in prone position. The delineation of the clinical target volume was done after fusion of
CT and MRI, with the help of a radiologist. For the IMAT plan, arcs were generated using an anatomy-
based segmentation tool. The optimization of the arcs was done by weight optimization (WO) and leaf
position optimization (LPO), both of which were adapted for IMAT purposes. The 3D plans used one
posterior and two lateral wedged beams, of which the outlines were shaped to the beam’s-eye view projection
of the planning target volume (PTV). Beam WO was done by constrained matrix inversion. For dose–volume
histogram analysis, all plans were normalized to 45 Gy as median PTV dose. Polymer gel dosimetry (PGD)
on a humanoid phantom was used for the validation of the total chain (planning to delivery). IMAT
treatments were delivered by an Elekta SliPlus linear accelerator using prototype software with the same
interlock class as in clinical mode.
Results: The IMAT plan resulted in 3 to 6 arcs, with a mean delivery time of 6.3 min and a mean of 456 monitor
units (MU) for a 180 cGy fraction. The minimal dose in the PTV was not significantly different between 3D and
IMAT plans. Inhomogeneity was highest for the IMAT plans (14.1%) and lowest for the 3D plans (9.9%). Mean
dose to the SB was significantly lower for the IMAT plans (12.4 Gy) than for the 3D plans (17.0 Gy). The volume
of SB receiving less than any dose level was lower for the IMAT plans than for 3D plans. Integral dose was lower
in the IMAT plans than for the 3D plans (respectively 244 J and 262 J to deliver 45 Gy). Differences between the
PGD measured dose and the calculated dose were as small for IMAT as for 3D treatments.
Conclusion: IMAT plans are deliverable within a 5–10-minute time slot, and result in a lower dose to the SB than
3D plans, without creating significant underdosages in the PTV. PGD showed that IMAT delivery is as accurate
as 3D delivery. © 2004 Elsevier Inc.Intensity–modulated arc therapy (IMAT), Rectal cancer, Small bowel toxicity.
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AINTRODUCTION
he use of radiotherapy, either preoperatively or postoper-
tively, in addition to systemic chemotherapy, decreases the
ocal recurrence rate and improves survival in rectal cancer
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2050401, BOF 01112300, 011VO497, 011F1700), and the Cen-7941). Randomized trials of preoperative radiation and surgery
s. surgery alone showed a radiation-dose dependent reduc-
ion of local failure in the combined modality arm, with a
alving of the local recurrence rate at biologically effective
oses of 30 Gy (2). Preoperative radiation therapy to a
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795Intensity-modulated arc therapy for rectal cancer ● W. DUTHOY et al.ose of 40–45 Gy in 1.8–2 Gy per fraction, usually com-
ined with 5-fluorouracil–based chemotherapy is the stan-
ard schedule in many European centers.
Although some reports suggest further improvement in
ocal control for higher doses, especially in high-stage rectal
ancer (3, 4), acute and chronic small bowel (SB) and rectal
oxicity (5) seem to limit further dose escalation. For small
owel, reported incidences of acute Grade III–IV diarrhea
ary between 15% and 40%, depending on grading systems,
ype of surgery, administration of adjuvant chemotherapy,
nd other variables such as comorbidity (6, 7). Chronic SB
adiation toxicity is irreversible and can be life-threatening.
ctuarial 5-year estimates of severe chronic SB toxicity
ary between 7% and 42% (8, 9) at doses of 45–50 Gy. The
ncidence of both acute and late SB toxicity is related to the
olume of SB in the treatment fields (6, 7, 9). Several
ossible methods have been examined for minimizing the
ortion of SB in the treatment field. For a review of these
ifferent techniques, the reader is referred to Letschert (10).
new possibility to reduce the volume of SB irradiated to
igh doses consists of intensity modulation (IM). IM offers
he possibility to spare an organ at risk (OAR) lying in the
oncavity of a planning target volume (PTV). This anatomic
elationship occurs in rectal cancer, where SB is partially
urrounded by the clinical target volume (CTV), consisting
f the rectum and its draining lymph node regions. Because
f the large internal radius of the concave PTV in rectal
ancer, a large number of beam directions may be favorable
11). With arc therapy, the number of beam directions is
nfinite, and thus intensity-modulated arc therapy (IMAT)
11, 12) might be a logical approach to this clinical problem.
he goals of this study are as follows: (1) to present our
lanning strategy and first experience of IMAT for rectal
ancer; (2) to report the results of a planning comparison
etween conventional radiotherapy (3D) and IMAT; (3) to
alidate the IMAT delivery method using polymer gel do-
imetry.
Table 1. Patient an
Patient
No.
RT
timing TNM Volsb3D (cc)
#
arcs
1 pre cT3 cN1 234.4 5
2 pre cT2 cN1 29.7 6
3 post pT3 pN0 22.6 6
4 post pT4 pN0 8.9 4
5 pre cT3 cN1 145.8 3
6 pre cT3 cN1 0.8 5
7 post pT3 pN1 146.3 4
Abbreviations: Volsb3D  the volume of small bowel receiving
ntensity-modulated arc therapy.
* The 7 patients are ordered chronologically. RT timing is the o
reoperative radiotherapy, and “post” for postoperative radiothera
For IMAT the number of arcs is given, as is the total number o
CDT) and dummy run delivery time (DRDT) is given. All time m
nto the wedged (W) and unwedged (UW) part.METHODS AND MATERIALS
elineation
Between February 2003 and November 2003, 7 patients
ith a histologically proven adenocarcinoma of the rectum
ere treated with IMAT. All patients signed an informed
onsent for inclusion in this feasibility study, approved by
he local ethics committee. Some clinical data of these
atients are shown in Table 1 A planning computed tomog-
aphy (CT) was performed with the patient in prone posi-
ion. For Patients 5, 6, and 7, a bellyboard was used
Sinmed, Reeuwijk, The Netherlands). CT slice thickness
as 0.3 cm, and the scanned volume extended from the
hird lumbar vertebra down to 10 cm caudal to the obturator
oramina. No contrast enhancement was used. No attempts
ere made to reduce variation of bladder filling. All patients
nderwent diagnostic magnetic resonance imaging (MRI),
hich was electronically fused with the planning CT. This
as done using the landmark method of the Oncentra Treat-
ent Planning System (Nucletron B.V., Veenendaal, The
etherlands). In those patients who were sent for preoper-
tive radiotherapy, the gross tumor volume (GTV) was
elineated using the fused CT-MRI. The fused CT-MRI was
lso used for the delineation of all other target subvolumes.
hese included the following structures: rectum, mesorectal
pace, presacral space and the lymph node regions along the
ommon iliac (up to and including the level of the first
acral vertebra), the internal iliac, the superior rectal, and
he internal obturator vessels. In patients with a tumor lying
cm or less from the anal verge, the perineal area was also
ncluded. The contouring of these target subvolumes was
one together with a radiologist (P.S.). Because the internal
otion of the different target subvolumes is different (13),
he rectum was expanded anisotropically with 1.5 cm in the
nteroposterior direction, and with 0.5 cm in the craniocau-
al and lateral directions. All other subvolumes were ex-
anded isotropically with 0.5 cm. All unexpanded subvol-
ning description*
IMAT 3D
#
Us
CDT
(mean  SD) DRDT
# MUs
(W/UW) DRDT
26 5.8  0.4 5.4 389/109 2.8
08 9.4  0.3 7.6 350/87 2.4
21 7.5  0.3 6.3 302/92 2.3
76 5.5  0.3 5.5 187/153 2.6
29 3.4  0.0 3.5 304/100 2.5
92 5.8  0.1 5.5 363/92 2.4
37 5.6  0.7 4.8 211/144 2.6
han 90% of the target prescription dose in the 3D plan; IMAT 
radiotherapy in relation to the surgery, in which “pre” stands for
tor units (MUs) for a fraction of 180 cGy. Clinical delivery time
ements are given in minutes. For the 3D plans, MUs are split upd plan
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step. Finally, a dose calculation with the CCC/S algorithm is done, and the plan is evaluated by the clinical staff.
796 I. J. Radiation Oncology ● Biology ● Physics Volume 60, Number 3, 2004mes were summed to form the CTV, whereas all expanded
ubvolumes were summed to the PTV.
The OARs that were contoured were bladder and SB.
ll SB loops were delineated individually up to the CT
lice through the middle of the fourth lumbar vertebra.
tructures provided to the optimization algorithm in-
luded the PTV, bladder, SB, and three structures gener-
ted to aid the optimization towards a desirable solution.
first optimization aid structure was made by subtracting the
TV and an additional margin of 0.6 cm from a 1-cm expan-
ion of the SB, resulting in the structure “small_bowel_ex-
_optim”. Other optimization aid structures were rim_2_cm
 all tissue between 0 and 2 cm around the PTV) and surr (
ll tissue more than 2 cm from the PTV). For a discussion
bout the use of these optimization aid volumes, the reader is
eferred to De Neve et al. (14). The anatomy-based segmen-
ation tool (ABST) (15) needs an OAR of which the projection
n the isocentric plane is larger than the PTV projection in the
irection perpendicular to the direction of the leaf motion. For
his reason, a segmentation structure (segm_str) was made,
onsisting of SB and bladder, elongated in the craniocaudal
irection when necessary. Per patient, the same target struc-
ures and OARs were used for both plans.MAT planning procedure
The IMAT planning procedure has been described in
ore detail previously (11) and is summarized in Fig. 1.
achine states (MSs) are generated using ABST every 8°
ithin the deliverable range. This deliverable range consists
f beam directions in which the radiation beam does not
raverse metal components of the couch before entering the
atient. In the case of the Elekta SLiPlus couch, the largest
eliverable range is obtained by positioning the metal C-
rms of the couch on 120° or 150°, as measured from their
ateral position. Considering the relative position of the
socenter to the table and the PTV geometry, possible gantry
ngles ranged from 136° to 136°. Thus, no arcs were
rradiating the patient from below the couch (anterior to the
atient). The ABST resulted in (maximally) four classes of
Ss per beam direction, differing from each other only in
he coverage of the PTV (Fig. 2). All adjacent MSs of the
ame class were sorted based on the gantry angle to form an
rc (Fig. 2), thus resulting in four arcs. These initial arcs
ere the input of the optimization, which is done by our
n-house developed segment outline and weight adaptation
ool (SOWAT), modified for IMAT purposes (aSOWAT)
Fig. 1). aSOWAT optimizes the leaf positions of each MSFig 1. Intensity-modulated arc therapy (IMAT) planning flowchart. Abbreviations: ADR  angular delivery rate;
aSOWAT  arc-therapy modification of segment outline and weight adaptation tool; CCC/S  collapsed cone
convolution/superposition calculation algorithm; MS  machine state. A MS is described by a set of machine
parameters that uniquely define beam direction, aperture, and photon beam quality. After MS generation, MSs of the
same class are then ordered into arcs. These arcs are given as input to aSOWAT. This is our optimization tool, which
was adapted for IMAT purposes. aSOWAT starts with a check of the leaf velocities in the transition from one MS to
the next. If necessary, leaf positions are adapted to meet this constraint. Then, the actual optimization starts with the
optimization of the monitor units (MU) per step, in which a step is defined as the transition from one MS to the next.
A factor is included in the biophysical cost function to restrict the MU per degree variation (ADR constraint). When a
user-defined number of cycles have been executed, aSOWAT is terminated, and the new MS outlines are saved. This
is followed by the interactive extraction of deliverable arcs with constant ADR. After all deliverable arcs have been
extracted, these are given as input to aSOWAT, but with optimization of the total number of MUs per arc instead of per
as
A
e
o
t
A
e
o
c
E
s
a
fl
l
n
e
d
e
A
e
e
o
i
d
E
l
i
t
z
T
c
a
s
t
A
t
f
l
d
a
w
T
797Intensity-modulated arc therapy for rectal cancer ● W. DUTHOY et al.nd the monitor unit (MU) values of each step, in which a
tep is defined as the transition from one MS to the next MS.
dditional to the previously described IMAT planning strat-
gy, a factor has been added to the objective function to
btain a fluent angular delivery rate (ADR). This factor
akes into account the first and second derivative of the
DR, approximated using the first and second finite differ-
nces of the MU values of each step. This first aSOWAT
ptimization results in arcs with a nonconstant ADR, further
alled virtual arcs, which are presently undeliverable on the
lekta SLiPlus linac. These virtual arcs, however, help to
elect the start and stop gantry angles of the final, deliver-
ble arcs, for which the ADR has to be constant. The
uently modulating ADR facilitates this extraction of de-
iverable arcs. To obtain a time-efficient treatment, the
umber of arcs has to be kept low. Consequently, a one-step
xtraction of deliverable arcs would impose a very rough
iscretization of the optimized ADR.
A more efficient procedure was implemented as follows:
ach arc is separately (and manually) extracted from the
DR graphs displayed on the planning computer. After
ach extraction of a deliverable arc, the MUs of all deliv-
Fig. 2. Anatomy-based arc generation shown in beam’s-e
Segm. str.  segmentation structure; MS  machine sta
passing at the left side of the segmentation structure; S1L
of the segmentation structure; S0R  MS covering the to
segmentation structure. S1RMS covering a 2-cm-wide
The ABST-generated machine states are shown for three
horizontal position shows how the different classes (S0L
vertical direction, the ordering per arc can be appreciat
segmentation structure does not differ much when the ga
not generated, because the width of the S0R MS was les
the S1R arc will end at a gantry angle of 8°.rable arcs are reoptimized, together with the remnant ADR
f the virtual arcs. During this short optimization, a factor
ncluded in the objective function favors the MUs of the
eliverable arcs with respect to the ADR of the virtual arcs.
ach extraction transfers MUs from the virtual to the de-
iverable arcs. By downforcing the remnant ADR, only the
mportant parts of the virtual arcs remain to be extracted in
he next deliverable arcs. When the remnant ADR falls to
ero by optimization, the extraction procedure is finished.
he plan is finalized by an aSOWAT optimization cycle,
onsisting of optimization of the leaf positions of the final
rcs, and optimization of the ADR per (extracted) arc in-
tead of per step, which is equivalent to optimization of the
otal MU-count of an arc (to be delivered at a constant
DR). A final dose computation was done for 18 MV using
he collapsed cone convolution/superposition algorithm
rom Pinnacle (Philips Medical Systems, Best, The Nether-
ands), which was used for all (IMAT and 3D) plans. Dose
istributions of arcs were approximated by computing dose
t the 8° interspaced MSs. For this, the MUs of each step
ere equally split and attributed to the two defining MSs.
hereby, the number of MUs assigned to the first and last
(BEV). Abbreviations: PTV planning target volume;
L  MS covering the total BEV projection of the PTV
S covering a 2-cm-wide area of the PTV at the left side
V projection of the PTV passing at the right side of the
f the PTV at the right side of the segmentation structure.
nt beam directions (gantry angles 0°, 8°, and 16°). The
S0R, and S1R) were generated per gantry angle. In the
can be seen, the BEV projection of the PTV and the
rotated over 8°. The S1R MS for the gantry on 16° was
the user-defined 2 cm for the S1R MS. This means thatye view
te; S0
 M
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798 I. J. Radiation Oncology ● Biology ● Physics Volume 60, Number 3, 2004S is the number of MUs of the arc divided by twice the
umber of steps. The MUs assigned to the other MSs is the
umber of MUs of the arc divided by the number of steps.
xcept where explicitly mentioned, all presented results on
MAT calculated dose distributions are based on this 8°
iscretization.
A last MU optimization per arc was done using the results
f the final dose computation. Finally, a prescription file
as generated for each arc, and networked to an Elekta
LiPlus 18-MV linear accelerator. The IMAT treatment
as delivered in local service mode using prototype dy-
amic software (Javelin, Elekta), with the same interlock
lass as used in clinical mode.
onventional planning
The conventional plan consisted of two lateral beams and
ne posterior beam, as described earlier. The outlines of the
eams were shaped conformally around the PTV with a
argin of 0.8 cm, using multileaf collimation. All beams
onsisted of a wedged and an unwedged part. The weight
ptimization was done using constrained matrix inversion
CMI) (16). It was proven previously that CMI resulted in a
etter plan than achieved by human planners, given that all
elevant structures are included in the objective function.
he following structures were used in the optimization
lgorithm: PTV, SB, and surr. The last structure was added
o avoid unacceptable overdosage outside the PTV.
reatment evaluation
Treatment delivery time, defined as the time between the
tart of the first arc and the end of the last arc, was measured
or all patients for nearly all fractions. Apart from these
linical time measurements, dummy run delivery time mea-
urements were done for all plans. For the IMAT plans, this
as done on Javelin, whereas for the 3D plans, this was
one on the RT Desktop (RTD) linac control software from
lekta. Total time was measured, as well as beam-on time,
ime for automatic setup, and time for system checks. For
he different planning techniques, the total number of MUs
eeded to deliver a 180 cGy fraction were also compared.
For dose–volume histogram (DVH) analysis, all plans
ere normalized to a median dose of 45 Gy in the PTV.
arget dose homogeneity was evaluated using an inhomo-
eneity factor U 
D99D1
Dmed
with D99 the dose below which
9% of the PTV volume was treated, D1 the dose below
hich 1% of the PTV volume was treated, and Dmed the
edian PTV dose. Furthermore, the D99 and D1 (used as a
urrogate for maximum and minimum dose, respectively),
nd the % volume of the target structure receiving more
han 95% of the prescribed dose over the total volume
V95%) were compared. For SB, the mean dose (Dmean), the
volume receiving more than 90% of the target prescription
ose (V90%), and the % volume receiving more than 15 Gy
V15Gy) were evaluated. Finally, the integral dose (DItotal)
iven to the patient was approximated as Dmean Vtot with Vtot
he total scanned volume. The dose deposition efficiency factorDDEF) was calculated by dividing the integral dose to the
TV (DIPTV) by DItotal. DVHs were recalculated for the group of
patients. For all relevant structures of all patients, the
olume percentiles at every 0.25 Gy dose level from 0 to 50
y were computed from the calculated dose distribution.
or every dose level, the mean and standard error of the
ean (SEM) was calculated. In order to characterize the
ifferent plans in their ability to spare SB, dose “volume
ifference” histograms (DVDH) were made. A DVDH rep-
esents the difference (between two plans) of the % volume
eceiving specified doses. DVDHs were constructed by cal-
ulating the mean (over the 7 patients) of difference in %
olume receiving a specified dose. These points were cal-
ulated every 0.25 Gy between 0 and 50 Gy. For all statis-
ical comparisons, a paired Student t test was used. All tests
ere two-tailed, and p  0.05 was considered statistically
ignificant.
osimetric verification
Polymer gel dosimetry (PGD) was used for dose verifi-
ation. The basis of this dosimetric technique resides in a
olymerization reaction of acrylic monomers within a hy-
rogel. The reaction is initiated by highly reactive radicals
hat are formed by radiolysis during irradiation. The amount
f polymer formed is related to the absorbed dose, and can
e quantified by MRI. Detailed information on PGD can be
ound elsewhere (17–19). A homogeneity study was done to
alidate PGD for the use of large volumes, and is described
lsewhere (20). A Barex (Cifra, Chateau Thierry, France)
ast was vacuum molded on the pelvic region of the
ANDO phantom (Alderson Research Laboratories, Stam-
ord, CT). Three supplemental RANDO slices were placed
ranially and caudally to the Barex phantom to have full
catter conditions in the gel during irradiation. CT scans
Siemens Somatom Plus 4, Erlangen, Germany) of the gel-
lled Barex phantom were transferred to the planning sys-
em, and the volumes of interest of a patient case were
ransferred to the CT set. For this setup, a 3D and an IMAT
lan were made as described earlier, and a prescription was
ade giving a median dose of 7.5 Gy to the PTV. This
nsured the maximal response range of the gel, while avoid-
ng saturation effects in the gel. Both techniques were
osimetrically verified using PGD. For the IMAT plan, two
easurements were done. First, the plan was delivered in
rc therapy mode, thus with dynamic gantry (IMATd). In a
econd experiment, the prescription was delivered in a dis-
rete way, i.e., as a static gantry IMRT with gantry positions
very 8° (IMATs). The latter delivery reflects how the plan
s calculated. By comparing both results, the effects of the
nterpolation from discrete, 8° interspaced, gantry positions
o arcs can be seen. For each experiment, gel-filled test
ubes were irradiated to doses between 0 and 10 Gy (every
Gy) for calibration purposes. The dose distributions, as
easured in the gel, were transferred to the planning sys-
em. For the transfer of the gel-measured dose distributions,
he following positioning procedure was followed: on both
he planning CT and the MRI (used for PGD), the content of
t
c
o
p
M
v
d
v
i
c
p
c
d
a
T
T
M
m
d
3
2
b
P
S
B
w
p
v
p
p
w
i
p
d
a
t
*
F
t
I
c
P
e
a
D
l
1 (solid lines) and for Patient 4 (dotted lines) are displayed in bold.
799Intensity-modulated arc therapy for rectal cancer ● W. DUTHOY et al.he Barex cast ( the gel) was automatically contoured. The
enter of volume (COV) of both structures was positioned
nto each other. Rotations were avoided by using laser line
ositioning on the CT scanner and positioning lines on the
RI scanner. The measured dose distribution was con-
erted to the prescription dose based on the planned vs.
elivered MUs. As a consequence, the comparison of con-
erted dose distributions is an absolute dosimetry compar-
son. The DVHs of all relevant structures, which were
lipped to the volume of the gel phantom (11), were com-
uted both for the calculated and the measured dose, and
ompared. Low’s -index (21) was calculated in 3D (dose
ifference criterion  5%, distance to agreement  5 mm),
nd -volume histograms (-VH) were reconstructed.
RESULTS
reatment plan and delivery
Details on the delivered IMAT plans are summarized in
able 1 Three to six arcs were used in the IMAT plans.
ean clinical delivery time was 6.3 min (range, 3.2–12.8
in) over all fractions and all patients. For the dummy run
elivery, the mean total delivery time was 5.5 min (range,
.5–7.6 min) for the IMAT plans, and 2.5 min (range,
.3–2.8 min) for the 3D plans (p 0.01). When considering
eam-on time only, this was 3.8  1.0 min for IMAT and
Table 2. Summary of the DVH data, showing the mean 
standard deviation
3D IMAT p Value
TV
V95 (%) 97.5  1.4 95.7  2.0 0.16
V107 (%) 0.0  0.0 0.2  0.3 0.13
D99 (Gy) 46.6  0.1 47.3  0.5 0.01*
D1 (Gy) 42.1  0.6 40.9  1.3 0.12
U (%) 9.9  1.5 14.1  3.1 0.03*
mall bowel
Dmean (Gy) 17.0  7.7 12.4  4.6 0.02*
V90 (%) 19.1  6.5 6.6  2.3 0.04*
V15Gy (%) 45.6  8.2 33.0  5.6 0.04*
ladder
Dmean (Gy) 34.6  6.8 18.2  2.7 0.01*
DItotal (J) 262.1  64.5 244.0  47.6 0.24
DDEF (%) 20.7  0.1 22.2  0.1 0.21
Abbreviations: 3D  conventional plan (three beam directions),
ith conformal portals; IMAT  intensity-modulated arc therapy
lan; PTV  planning target volume; V90, V95, and V107  partial
olume (%) receiving more than 90%, 95%, and 107% of the
rescribed dose, respectively; D1 and D99  the first and the 99th
ercentile dose; U  inhomogeneity factor, defined as
D99  D1	
Dmed
,
ith Dmed the median dose; Dmean  mean dose; DItotal  the
ntegral dose defined as the mean dose in the total volume multi-
lied by its volume, (DItotal was calculated for the total treatment
ose, 45 Gy); DDEF  dose deposition efficiency factor, defined
s DIPTV/DItotal; p values represent the result of a two-tailed paired t
est.
Statistically significant.ig. 3. Dose volume histograms (DVHs) compiled from the data of
he whole group. Solid lines and black-filled circles represent the
MAT plans; the 3D plans are shown by the dotted lines and open
ircles. For reasons of clarity, all circles were omitted for CTV and
TV. For each plan and each structure, the mean  the standard
rror of the mean is represented. Data are shown for CTV, bladder,
nd surr (a), and PTV and small bowel (b). In (c), the individual
VHs for the 7 patients are shown, both for the 3D plans (gray
ines) and for the IMAT plans (black lines). The DVHs for Patient
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ystem checks was 1.3 min for the IMAT delivery on the
avelin, and 0.4 min for the 3D plans on the RTD. For the
MAT plans, the number of MUs needed for a fraction of
80 cGy varied between 337 and 529 MUs (mean, 456 74
Us). For the 3D plans, this varied between 340 and 498
Us (mean, 412  56). This difference was not significant
p  0.16).
VH analysis and dose distributions
The compiled DVH data for the 7 patients are summa-
ized in Table 2, and graphically displayed in Fig. 3. The
inimal dose in the PTV was not significantly different.
nhomogeneity, however, was lower for the 3D plans (9.9%
1.5) than for the IMAT plans (14.4%  3.1). This
ifference was significant (p  0.03). Maximal dose in the
TV was 46.6 Gy for the 3D plans and 47.3 Gy for the
MAT plans (p  0.01). For the CTV, the inhomogeneity
or the 3D and IMAT plans was 6.3% and 8.1% (p  0.06).
he mesorectal space, surrounding the rectum, received a
lightly higher dose in the IMAT plans than in the 3D plans,
ith a maximal dose of 47.0 Gy vs. 46.3 Gy (p  0.01). In
he 3D plans, no part of the mesorectal space received a
ose higher than 107% of the prescribed dose, while the
107 was 0.1% for the IMAT plans. This difference was not
ignificant (p  0.1). For SB, the D99 was 45.5 Gy for the
D plans and 41.5 Gy for the IMAT plans. Mean dose to the
B was significantly lower for the IMAT plans, as was the
and the V . The absolute volume of SB receiving
Fig. 4. Dose volume difference histograms (DVDH) for
line), and surr (dashed line). The gray dotted line represe
for the small bowel (in cc). The D(A) VDH is constructed
in which VX is the % volume (or the absolute volume fo
 x  50 Gy with an 0.25 Gy increment of x. Positive
in the 3D plans than in the IMAT plans.15Gy 90ore than 15 Gy was 158 cc (range, 21–327 cc) in the 3D
lans, and 128 cc (range, 13–305 cc) in the IMAT plans.
he absolute V90 was 84 cc (range, 1–234 cc) and 27 cc
range, 0–58 cc) for the 3D and IMAT plans, respectively.
igure 4 shows the DVDH for SB, PTV and surr for 3D
lans compared to the IMAT plans. This illustrates that the
olume of SB receiving any dose is lower for the IMAT
lans. The differences in relative volume between 3D and
MAT plans for SB were significant between 13.5 and 42.5
y. For the PTV, the DVDH shows the underdosage and
verdosage caused by IMAT when compared to 3D. Be-
ween 42.25 and 45 Gy, 1–5% of the volume of the PTV
eceived less by IMAT than by 3D. The bladder received a
ignificantly lower dose in the IMAT plans, with a relative
eduction of nearly 50% in Dmean. The dose to the surr was
owest for the IMAT plans, with a mean V30Gy of 9.0% and
.4% for the 3D and IMAT plan, respectively. This is also
eflected in the average DDEF, which was 20.7% for the 3D
lans and 22.2% for the IMAT plans. This difference was
ot significant, but shows that IMAT is at least as efficient
s the 3D technique in dose deposition in the PTV.
Dose distributions for both an IMAT and a 3D plan are
hown in Fig. 5. The concave sparing of the SB by the
MAT plan is clearly visible in the three planes. The isodose
ines are highly conformal to the PTV form for the IMAT
lan. The dose outside the PTV is distributed over a large
olume in the IMAT plan, which can also be derived from
he DVDH (Fig. 4), which shows that IMAT results in
eposition of low dose (between 0 and 11 Gy) in a larger
g target volume (PTV) (solid line), small bowel (dotted
dose absolute volume difference histogram (DAVDH)
otting the mean (over the 7 patients) of (VX3D  VXIMAT),
DH) receiving dose x. Points were calculated for 0 Gy
indicate that the volume irradiated to dose x was largerplannin
nts the
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ines (Fig. 5a), especially in the low-dose region, caused by
he discrete gantry angle calculations.
osimetric verification
The results of the PGD are summarized in Table 3 and in
igs. 6 and 7. Table 3 shows the volumes of the clipped
tructures, and the relative differences between the mea-
Fig. 5. Dose distributions for Patient 5, showing the
transverse (a), sagittal (c), and coronal (e) plane. The 3
values are in Gy. The planning target volume is delineate
line.ured and the calculated values for some clinically impor-
ant parameters. The relative differences in Dmed were in-
ignificant, and varied between 1.1% for the 3D plan and
.3% for the IMATd experiment. The relative difference in
aximal PTV dose (D99) was nowhere larger than 4%, with
he largest difference found for IMATs (4.0%). For all
echniques, the D99 was underestimated by the dose calcu-
ation algorithm, while the minimal dose (D ) was overes-
ed intensity-modulated arc therapy (IMAT) plan in a
s (b, d, f) are shown in the same three planes. Isodose
dark dotted line, small bowel is shown by a light dotteddeliver
D plan
d by a1
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802 I. J. Radiation Oncology ● Biology ● Physics Volume 60, Number 3, 2004imated by 2.5% in IMAT, irrespective of the delivery
static vs. dynamic gantry). The partial volume of the PTV,
n which the -index was higher than 1 (V1), was no-
here higher than 2%. No clear difference was found be-
ween the IMATs and IMATd results. For SB, the relative
ifference in Dmean was largest for the 3D experiment
5.6%), and smallest for both IMAT experiments (1%).
he V1 for SB was 9.7% for IMATd, although there is
early no difference between calculated and measured dose
hen looking at the DVHs (Fig. 7a). The largest differences
etween measured and calculated dose were seen for blad-
er, for which the mean measured dose was up to 12%
igher than the calculated dose (this was for IMATs). This
s reflected in the high V1 for IMATs (6%) and IMATd
11.8%). The V1 for the total scanned volume was lowest
or the IMATd (6.4%) and highest for the IMATs (10.2%)
elivery. On Fig. 7, the same data can be found. It shows the
ood correlation between the measured and calculated dose
or PTV. It is also clear that there is no substantial differ-
nce between the IMATs and the IMATd delivery. The
VHs for bladder show a higher measured than calculated
ose in all cases, and this is most pronounced in the IMAT
eliveries. For SB and surr, DVH comparison shows no
linically relevant differences. Calculated and gel-measured
Table 3. Summary of the results of the polymer gel dosimetry
Voltrunc
(cc) 3D IMATs IMATd
TV 952 (97%)

 Dmed (%) 1.1 0.3 0.3

 D99 (%) 2.1 4.0 3.2

 D1 (%) 0.3 2.8 2.4
Vol  1 (%) 0.0 1.6 1.1
mall bowel 427 (82%)

 Dmean (%) 5.6 0.5 0.5

 V90% (%) 1.3 1.8 2.1

 V15Gy (%) 8.4 3.9 0.1
Vol1 (%) 1.6 6.1 9.7
ladder 124 (100%)

 Dmean (%) 3.1 12.0 9.9
Vol  1 (%) 0.0 6.0 11.8
urr 6298 (36%)
Vol  1 (%) 11.7 9.4 5.3
canned volume
Vol  1 (%) 9.0 10.2 6.4
Abbreviations: PTV  planning target volume; Voltrunc  the
olume of the structure, clipped to the volume of the MRI-
easured gel phantom (The percentage between brackets is the
artial volume of the structure in the gel phantom); IMATs  the
MAT treatment, delivered to the gel phantom in a static gantry
ode; IMATd  the IMAT treatment, delivered to the gel phan-
om in dynamic gantry mode; 
 Dmed  relative difference be-
ween measured and calculated mean dose, calculated as
medgel  Dmedcalc
Dmedcalc
, with Dmedgel the median dose in the specified
rgan, as measured by gel dosimetry, and Dmedcalc the median dose
s calculated (The same reasoning was followed for 
 D99, 
 D1,
Dmean, 
 V90%, and 
 V15Gy); Vol  1  the partial volume
f the clipped structure in which the -index was higher than unity.ose distributions are shown in Fig. 6. The ripples in the
ow-dose region, which are a consequence of the gantry
ngle discretization that is done for planning and calcula-
ions, are also obvious in the IMATs measured dose distri-
utions (Fig. 6c). They disappear when the dose computa-
ion is done for MSs, interspaced by 2° instead of 8° (Fig.
b), which more closely resembles the results of the IMATd
elivery (Fig. 6d). This IMATd is the delivery mode used in
he clinical IMAT execution.
DISCUSSION
Although not significant, the minimal dose was lower for
he IMAT plans. The same can be seen for the V95 of the
TV, which was lower for the IMAT plans. Still, on the
VH (Fig. 3b), it is clear that this underdosage is rather
mall. The PTV underdosage is partially caused by the SB
paring. The possibility to create concave dose distributions
ith IMAT leads to a larger PTV surface adjacent to the
ose gradient. This, in combination with the leaf position
ptimization, can result in the observed underdosage, lo-
ated at the borders of the PTV. Although the PTV under-
osage in this group was deemed not to be clinically rele-
ant, assigning a too high importance for SB in the
ptimization could result in relatively large dose “erosion”
t the margins of the PTV. For this reason, we defined the
ollowing PTV acceptance criteria for future use in IMAT
lanning for rectal cancer, based on the results of the present
nalysis. For the following criteria, we took the observed
ean  1 SD, thus resulting in (1) a V95  93.7%, (2) a D1
88% of the target prescription dose (for a prescription to
5 Gy, this is 39.6 Gy), and (3) a V107  0.5%. In case of
violation of one of the first two criteria, the IMAT plan
hould be reoptimized with lower SB importance. The third
riterium should not be an absolute one, as the higher
aximal dose (and more generally the higher inhomogene-
ty) is presumably caused by the discretization to deliver-
ble arcs: ADR cannot be modulated in a fine sense due to
he required constant ADR. Peaks visible in the ADR graphs
annot be expressed in the final arcs as the Elekta linac is
ot able to fluently deliver short arcs. Balancing the linac
sing counterweights and optimization of the settings of the
antry servo-system reduced the problems, but arcs smaller
han 56° still cause too many interrupts to be practical. The
ddition of a few static gantry intensity-modulated beams
replacing the practically undeliverable short arcs) to the
MAT arcs may reduce inhomogeneity in the PTV. This
ossibility has not yet been explored. During planning, it is
lear that the arc extraction procedure significantly reduces
he quality of the plan (PTV inhomogeneity and dose to the
ARs increase, data not shown). This is (partly) solved by
eaf position optimization. Earl et al. (22) also discuss the
imitations imposed by the constant ADR, and showed that
dding an additional arc could reduce this plan deteriora-
ion, but that a variable dose rate or gantry speed would
olve this problem. We prefer the implementation of a
ariable gantry speed over the variable dose rate. In this
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803Intensity-modulated arc therapy for rectal cancer ● W. DUTHOY et al.ay, the optimization even has the possibility to insert a
tatic gantry IM beam as a part of an arc by lowering the
antry speed to 0°/min. This solution, which delivers the
ptimized nonconstant ADR, also reduces the number of
rcs, the total gantry rotation, and most probably also the
lanning and treatment time. It also removes the complex
lanning step of arc extraction. We plan to investigate the
ull impact of variable ADR on planning quality and deliv-
ry time.
Intensity-modulated arc therapy offers the possibility to
pare SB and bladder in comparison with a 3D technique. A
elative reduction of 28% in Dmean can be seen for SB. For
he V90, a relative reduction of 65% was reached by apply-
ng IMAT. The V15Gy, which was found to be strongly
ssociated with acute SB toxicity by Baglan et al. (6), was
educed by 28%. Whether this sparing of the SB on the
lanning level will translate into a clinically diminished SB
oxicity is beyond the scope of this study, which was fo-
used on clinical implementation of IMAT and its planning
Fig. 6. Dose distributions of the intensity-modulated arc t
as it was calculated (a, b) and measured by polymer gel do
are shown for the IMAT plan, with calculated control p
control points were generated and calculated every 2°
measured IMAT plan, delivered to the phantom in a discr
with 8° interspaced beams. (d) The measured IMAT plaomparison with a 3D technique. In the present series, the
olume of SB receiving 90% of the target dose in the 3D
lans (Volsb3D) was rather small (mean, 84 cc; range, 1–234
c) compared to previous reports (6, 9). This might under-
stimate the full potential of IMAT, as we could expect a
orrelation between the Volsb3D and the relative reduction in
90, obtained by IMAT over 3D. A DVH analysis for the
ubgroup of patients with a Volsb3D greater than 84 cc shows
V90 of 32.3% and 9.6% for 3D and IMAT, respectively.
or the other 4 patients, the V90 was 9.2% and 4.4%. Of
ourse, the number of patients is too small to draw strong
onclusions, but we hypothesize that the IMAT technique
ets more efficient as the anatomic situation is more com-
lex. Some subgroups of patients might have a large im-
rovement of their treatment plan quality by IMAT, while
he effect might be negligible or clinically irrelevant in
thers. It was shown that patients who receive postoperative
adiotherapy have a larger portion of (fixed) SB in the pelvis
23). These patients are also at higher risk for SB toxicity
(IMAT) plan in a transverse plane through the isocenter
y (c, d). Isodose values are in Gy. In (a), the calculations
very 8°. In (b), the same plan is shown, but additional
terpolation of the preexisting control points. (c) The
y, i.e. as a static gantry intensity-modulated radiotherapy
vered in dynamic gantry mode.herapy
simetr
oints e
by in
ete wa
804 I. J. Radiation Oncology ● Biology ● Physics Volume 60, Number 3, 2004Fig. 7. Dose–volume histograms (DVHs) (a, c, e) and -volume histograms (b, d, f) for the three polymer gel
experiments. In (a, c, e), the dashed lines represent the calculated DVHs, while the solid lines represent the gel-measured
DVHs. The DVHs and -VHs are shown for planning target volume, small bowel, bladder, and surr. The -VHs for the
total measured volume are also shown (bold curve). Results are shown for the dynamically delivered intensity-
modulated arc therapy (IMAT) treatment (a, b); the statically delivered IMAT plan (c, d), and for the 3D plan (e, f).
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805Intensity-modulated arc therapy for rectal cancer ● W. DUTHOY et al.han patients who received their radiotherapy in a preoper-
tive setting (24). Besides this group of postoperatively
reated patients, other patients who might benefit from
MAT could be selected by means of investigations such as
olumetry of the contrast-filled SB during simulation.
The delivery time of the 3D treatments was significantly
horter than for the IMAT treatments. As mentioned, the 3D
reatments were delivered using the RTD. The RTD system
perates with a dose rate of550 MUs/min (compared to 130
r 260 MUs/min for most of the arcs), and has a faster
hecking system than the prototype dynamic software used for
MAT. Thus, although clinical IMAT delivery time is within a
tandard time slot at the moment, it could be reduced even
urther by adaptations to the linac control software.
Quality assurance of a complex technique like IMAT
emains a challenge. As both the gantry and the leaves are
onstantly moving, tracking their position is not easy. Ram-
ey et al. (25) developed an elegant method to evaluate the
eaf position errors during arc delivery, based on the logs of
Varian Clinac MLC, and derived a formula to estimate the
onsequent dosimetrical error. Our strategy was to check the
nd-of-chain result. Different methods, such as ion chamber
oint dosimetry and 2D film dosimetry, have been used by
thers (22, 26). Although valuable, these techniques do not
ffer the possibility to evaluate the IMAT treatment in three
imensions, whereas dose distributions of IMAT treatment
lans typically vary in three dimensions. PGD offers abso-
ute dosimetry in three dimensions with a high resolution.
ergote et al. (20) optimized PGD for its use in large
hantoms. This resulted in a structural root-mean-square
eviation between gel-measured and Helax-TMS computed
ose distributions of 2% (except in high dose gradient
egions, where it was 5%) and a stochastic deviation of 2%,
esulting in an accuracy of 2.8% (and 5.4% in high dose
radient regions). We found a good correlation between
el-measured and calculated dose distributions for the PTV
V1  1.1%). The SB sparing, obtained by the IMAT
echnique, was confirmed by the PGD measurements. These
esults ensured us that IMAT planning, calculation, and
elivery were accurate and could be implemented in a
linical setting. The largest deviations were seen for blad-
er, with a calculated vs measured Dmean of 23.7 Gy and
6.0 Gy in the IMATd experiment (9.9%). Nearly the full
ose contribution to the bladder is due to scatter and trans-
ission, as the bladder is shielded in all arc apertures.
alculation errors in the computation of both scatter dose
nd transmission can thus have a high impact on the calcu-ated dose of the bladder. PGD also showed that the inter-
olation of the 8° angularly interspaced control points to an
rc does not produce different dosimetrical results than if it
ere given as static gantry IM beams. As previously dem-
nstrated (20, 26), decreasing the interspacing distance from
° to 2° affects the dose distribution for the low-dose
egions (the ripples disappear), whereas for high dose re-
ions, there is little or no difference.
To our knowledge, there has been no report on clinically
xecuted IMAT or even intensity-modulated radiotherapy
IMRT) treatment for rectal cancer until now, despite the
act that IMRT has been used in a clinical setting for nearly
decade now. There is one report of a planning comparison
etween IMRT and 3D (27). The authors found a relative
eduction of 55% to 72% in V95 for SB, depending on the
TV inhomogeneity that was tolerated. This is in the same
ange as our findings, with a V95 for SB 72% for IMAT. In
elvic radiotherapy, the first clinical results about the im-
lementation of IMRT for gynecologic malignancies have
een published. Mundt et al. have shown that IMRT reduces
oth acute (28) and chronic (29) SB toxicity in comparison
o conventional treatment. In cervical cancer, as in rectal
ancer, the internal iliac and obturator nodes are important
outes of nodal spread, leading to a concave shaped PTV
artially encompassing bladder and SB. Therefore, we hy-
othesize that a similar toxicity reduction can be achieved in
ectal cancer patients as in patients with cervical cancer.
Whether IMAT will prove to be the best option for rectal
ancer irradiation (and for other sites) in the future will
argely depend on the improvement of IMAT. A large
indow for improvement exists for IMAT, including plan
ptimization and automation of the planning process, and
mprovements of the linac control software, of which vari-
ble gantry speed is the single most important.
CONCLUSION
Seven patients with rectal cancer were irradiated with
MAT. On planning, IMAT allowed one to spare SB as
ompared to a conventional 3D technique, without compro-
ising the dose in the PTV. Although treatment time for
MAT was longer in comparison to a 3D technique, it was
eliverable within a time slot of 5–10 min. Three-dimen-
ional PGD showed that IMAT delivery is as accurate as 3D
elivery. We identified significant potential for improve-
ents both at the levels of planning and delivery. The single
ost important technical improvement for IMAT is the
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